Otrivin Advance (Xylometazoline Hydrochloride, Ipratropium Bromide)

Xylometazoline is an alpha‑adrenergic agonist that binds to receptors on the smooth muscle of nasal blood vessels, causing vasoconstriction. This narrowing of vessels reduces blood flow to the nasal mucosa, decreasing swelling and opening the airway for easier breathing.

The specific dose and frequency of Otrivin Advance are determined by the prescribing healthcare professional based on the patient’s age, condition, and response to therapy. Patients should follow the prescriber’s instructions and not exceed the recommended number of sprays per day.

Safety data for Otrivin Advance in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with single‑agent decongestants, Otrivin Advance offers a dual mechanism: xylometazoline provides vasoconstriction while ipratropium reduces secretions. This combination can be more effective for mixed congestion and rhinorrhea, but the risk of rebound congestion remains if used beyond the recommended duration.

Store Otrivin Advance at room temperature, preferably below 25 °C. Keep the spray in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed to maintain product stability.

Otrivin Advance is administered as a nasal spray. The patient tilts the head slightly forward, inserts the nozzle into one nostril, and gently presses the pump to deliver the recommended number of sprays. The process is repeated in the other nostril if directed by the prescriber.

Serious risks include rebound nasal congestion (rhinitis medicamentosa) after prolonged use, severe nasal ulceration, allergic reactions such as anaphylaxis, and increased intra‑ocular pressure in patients with glaucoma. Any of these symptoms require immediate medical attention.

Otrivin Advance should not be used by children under six years of age, individuals with narrow‑angle glaucoma, severe hypertension, or known hypersensitivity to xylometazoline, ipratropium, or any excipients in the formulation. Contra‑indications must be confirmed by a healthcare professional.